Summary
63 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 163 USD is left as net profit.
- It holds more cash than debt: $196.6M against $64.8M.
- You pay 0.6 USD for 1 USD of yearly profit, little for its sector.
What to watch
- Revenue fell by 5.8% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 0.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.8% a year over 5 years. Over the last 3 years it fell by 5.8% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 37 USD
- Research and development 1.7 USD
- Sales and administration 104 USD
- Taxes and other -206 USD
- Net profit 163 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 163 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $5 is 167% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Qbrexza 49%
- Accutane 38%
- Amzeeq 9.8%
- Zilxi 3.2%
By region
The company reports no revenue by region.
Qbrexza brings in 49% of revenue. Accutane grew fastest, by 25% a year.
Segments in detail